Candida tropicalis Bloodstream Infection (Candidemia)

What is C. tropicalis?

Epidemiology & Risk Factors

• Neutropenic patients with hematologic cancers receiving cytotoxic chemotherapy and corticosteroids (classic host)
• ICU patients - broad-spectrum antibiotics, indwelling central venous catheters, parenteral nutrition, renal failure, dialysis, pancreatitis, high APACHE score
• Diabetes mellitus
• Recent abdominal/thoracic surgery
• Burn victims
• Solid organ transplant recipients
• HIV/AIDS (primarily mucocutaneous, but invasive in late disease)

Clinical Presentation

• Retinal lesions (Candida endophthalmitis) - can progress to endophthalmitis and blindness
• Chronic disseminated ("hepatosplenic") candidiasis - multiple microabscesses in liver/spleen, especially post-neutropenia recovery
• Candida endocarditis (rare, more common in IV drug users or prolonged candidemia)
• Osteoarticular infection, CNS involvement

Diagnosis

Blood Cultures

• Standard first-line test but not fully sensitive - up to 50% of invasive infections may be blood-culture negative
• Takes 1-4 days for growth (problematic in critically ill patients)
• All positive blood cultures for Candida require treatment - even a single positive bottle

Non-culture-based Methods

• β-D-glucan assay: Candida cell wall component; moderate sensitivity in high-risk patients; not specific (also positive in Aspergillus, PCP)
• PCR: More sensitive than blood cultures or β-D-glucan; not yet standardized widely
• Magnetic biosensor technology (newer): identifies Candida species rapidly from whole blood

Additional Workup Once Candidemia Confirmed

1. Dilated fundoscopic exam (by ophthalmologist) - rule out retinal lesions in ALL candidemic patients
2. Echocardiography - rule out endocarditis
3. Remove and culture CVC tip - any yeast growth is significant
4. Imaging (CT abdomen) - for chronic disseminated candidiasis or organ abscesses
5. Repeat blood cultures - to confirm clearance

• Goldman-Cecil Medicine, 22nd Ed.

Treatment

First-line: Echinocandins (preferred for ALL patients)

Fluconazole (acceptable alternative)

• 400-800 mg/day IV/oral
• Only appropriate if:
  • Patient is not severely ill / hemodynamically stable
  • Isolate is unlikely to be azole-resistant (C. tropicalis can develop fluconazole resistance)
• Confirmed-susceptible isolates: can step down from echinocandin to fluconazole once patient stabilizes

Step-down therapy

• After clinical stabilization + confirmed susceptible isolate: transition to fluconazole orally
• Voriconazole is an alternative step-down but offers no advantage over fluconazole
• Isavuconazole is not approved for candidemia (inferior to caspofungin in trials)

Duration

• Minimum 2 weeks after the first negative blood culture, AND resolution of symptoms/signs
• In neutropenic patients: continue until neutrophil recovery

Source Control (critical)

• Remove central venous catheter as soon as feasible - proven to hasten blood-culture clearance
• Endocarditis: lipid amphotericin B 3-5 mg/kg/day ± flucytosine 25 mg/kg QID x 6 weeks + valve replacement

Amphotericin B

• 0.7 mg/kg/day (conventional) or 3-5 mg/kg/day (lipid formulation)
• Reserved for: neutropenic patients, neonates, severe/refractory cases, endocarditis
• Goldman-Cecil Medicine, 22nd Ed.; Fitzpatrick's Dermatology, 5th Ed.; Red Book 2021

C. tropicalis-Specific Concerns

Summary of Management Algorithm

Suspected candidemia (fever + risk factors)
       ↓
Blood cultures x2 + beta-D-glucan + remove CVC
       ↓
Start empiric echinocandin immediately
       ↓
Ophthalmology exam + echo + repeat blood cultures
       ↓
Species identification + susceptibility testing
       ↓
C. tropicalis confirmed susceptible to fluconazole?
  → YES + patient stable: Step down to fluconazole
  → NO / resistant: continue echinocandin
       ↓
Treat 14 days from first negative blood culture